Recipharm in discussions with Alcon regarding long-term manufacturing agreement

Recipharm in discussions with Alcon regarding long-term manufacturing agreement

Sept. 7, 2015 - Recipharm in discussions with Alcon regarding long-term manufacturing agreement

Recipharm is currently in discussions with Alcon and has reached agreement in principle to enter into a long-term manufacturing agreement for a range of ophthalmology products. As part of this arrangement, Recipharm will also acquire Alcon's manufacturing facility located in Kaysersberg, France.  The 260 people currently employed at the Kaysersberg site would transfer and continue to be offered employment by Recipharm following the date of the sale. Further details will be made available following the end of consultation with the Works Council of Alcon and finalisation of the negotiations.

For more information please visit www.recipharm.com or contact: Björn Westberg, CFO, [email protected], +46 8 602 46 20 Mark Quick, EVP Corporate Development, [email protected], +44 1 925714263 This information is published in accordance with the Swedish Securities Market Act, the Swedish Financial Instruments Trading Act and/or the regulations of NASDAQ Stockholm.

This information was submitted for publication on 7 September 2015, at 08:30 am CET.

About Recipharm

Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,200 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm's turnover is approximately SEK 3.3 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com Recipharm AB (publ) Corporate identity number 556498-8425 Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52 00, Fax 46 8 81 87 03 www.recipharm.com

Suggested Articles

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.